Darunavir - first molecule to treat drug-resistant HIV

Published on August 2, 2006 at 6:40 PM · No Comments

Doctors have their first FDA-approved tool to treat drug-resistant HIV thanks to a new molecule created by a Purdue University researcher.

"There are many treatments for AIDS on the market, but none are able to combat drug resistance," said Arun Ghosh (pronounced A-rune GO-sh), a professor with a dual appointment in the departments of chemistry and medicinal chemistry and molecular pharmacology. "This is the first treatment that is effective against the growing number of drug-resistant strains of HIV, the virus that causes AIDS. The problem is widespread."

The FDA recently approved the pill-based therapy of Ghosh's molecule, TMC-114, for medical use. The molecule, also known as Darunavir (pronounced DA-rune-a-veer), is the forerunner in a series of molecules under development by Ghosh.

Earlier research shows that almost half of patients with the human immunodeficiency virus (HIV) who initially respond to treatment develop drug-resistant strains and stop responding to treatment within eight to 10 months, he said. An additional 20 percent to 40 percent of patients have drug-resistant strains when they are first diagnosed, suggesting these strains can be transmitted from one person to the next.

This year marks the 25th anniversary of the first reported U.S. cases of AIDS, a disease that claims the lives of more than 15,000 Americans each year, according to the Centers for Disease Control and Prevention. World Health Organization figures estimate more than 40 million people worldwide are infected with HIV.

For years the virus has frustrated drug developers through its ability to "outsmart" therapies. The virus rapidly mutates and, as parts of its structure change, it becomes resistant to treatment. Previously, patients with drug-resistant strains were out of options and had greatly reduced life expectancies.

"My only wish was that my design would help people and alleviate suffering," Ghosh said. "I'm so grateful it has turned into a drug and been approved by the FDA so quickly."

The molecule Ghosh created is expected to be available to physicians this year, he said.

"I think that this drug will have a sizeable impact on the current therapy for AIDS and HIV infection," said Hiroaki Mitsuya (pronounced HE-row-ah-key MIT-sue-ya), chief and principal investigator of the Experimental Retrovirology Section at the National Cancer Institute who collaborated with Ghosh in this research.

Molecules are made up of groups of atoms bonded together. These bonded groups form an oddly shaped structure with sections that branch off and others that form loops. Different sections are responsible for various behaviors of the molecule.

Ghosh's designed compound has selected features of naturally occurring molecules that improve its ability to fight HIV. The result is a variation of one of the most common treatments existing today, a protease inhibitor.

Protease is an enzyme necessary for HIV to reproduce properly. A protease inhibitor binds to protease, making it unusable by the virus. Without the use of protease, HIV is incapable of infecting cells and harming the patient. By reducing the amount of active virus, patients' bodies have an increased ability to fend off opportunistic infections, the leading cause of death for those with AIDS.

Eight protease inhibitors are currently on the market and have greatly improved the quality of life for those suffering from HIV, Ghosh said. These inhibitors, however, lose their effectiveness over time, often cause severe side effects and are ineffective against drug-resistant HIV strains, he said.

Treatment using the molecule designed by Ghosh has fewer associated side effects because the dose required is significantly less than those for existing protease inhibitors. The molecule also is smaller than those that make up current protease inhibitors and is much more easily absorbed and tolerated by the body, according to research results.

"In Phase 3 clinical trials of TMC-114, the majority of patients receiving the drug did very well with relatively few side effects," Mitsuya said. "Those patients showed a significant increase in their CD4 cell counts. Many of those patients have been treated for a year or more and have shown no signs of developing a significant resistance to the drug."

Ghosh is now expanding on his design, making alterations to the original molecule aimed at making even more effective treatments.

"The most recent protease inhibitors we created are exceedingly potent," he said.

Ghosh's work has opened the door to a new path for antiretroviral therapy.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post